Effect of the 2017 European Guidelines on Reclassification of Severe Aortic Stenosis and Its Influence on Management Decisions for Initially Asymptomatic Aortic Stenosis
- PMID: 33287584
- DOI: 10.1161/CIRCIMAGING.120.011763
Effect of the 2017 European Guidelines on Reclassification of Severe Aortic Stenosis and Its Influence on Management Decisions for Initially Asymptomatic Aortic Stenosis
Abstract
Background: The 2017 European Society of Cardiology guidelines for valvular heart disease included changes in the definition of severe aortic stenosis (AS). We wanted to evaluate its influence on management decisions in asymptomatic patients with moderate-severe AS.
Methods: We reclassified the AS severity of the participants of the PRIMID-AS study (Prognostic Importance of Microvascular Dysfunction in Asymptomatic Patients With AS), using the 2017 guidelines, determined their risk of reaching a clinical end point (valve replacement for symptoms, hospitalization, or cardiovascular death) and evaluated the prognostic value of aortic valve calcium score and biomarkers. Patients underwent echocardiography, cardiac magnetic resonance imaging, exercise tolerance testing, and biomarker assessment.
Results: Of the 174 participants, 45% (56/124) classified as severe AS were reclassified as moderate AS. This reclassified group was similar to the original moderate group in clinical characteristics, gradients, calcium scores, and remodeling parameters. There were 47 primary end points (41 valve replacement, 1 death, and 5 hospitalizations-1 chest pain, 2 dyspnea, 1 heart failure, and 1 syncope) over 368±156 days follow-up. The severe and reclassified groups had a higher risk compared with moderate group (adjusted hazard ratio 4.95 [2.02-12.13] and 2.78 [1.07-7.22], respectively), with the reclassified group demonstrating an intermediate risk. A mean pressure gradient ≥31 mm Hg had a 7× higher risk of the primary end point in the reclassified group. Aortic valve calcium score was more prognostic in females and low valve area but not after adjusting for gradients. NT-proBNP (N-terminal pro-brain-type natriuretic peptide) and myocardial perfusion reserve were associated with the primary end point but not after adjusting for positive exercise tolerance testing. Troponin was associated with cardiovascular death or unplanned hospitalizations.
Conclusions: Reclassification of asymptomatic severe AS into moderate AS was common using the European Society of Cardiology 2017 guidelines. This group had an intermediate risk of reaching the primary end point. Exercise testing, multimodality imaging, and lower mean pressure gradient threshold of 31 mm Hg may improve risk stratification. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01658345.
Keywords: aortic valve; biomarkers; calcium; exercise; heart diseases.
Comment in
-
Letter by Radico et al Regarding Article, "Effect of the 2017 European Guidelines on Reclassification of Severe Aortic Stenosis and Its Influence on Management Decisions for Initially Asymptomatic Aortic Stenosis".Circ Cardiovasc Imaging. 2021 Apr;14(4):e012383. doi: 10.1161/CIRCIMAGING.121.012383. Epub 2021 Apr 9. Circ Cardiovasc Imaging. 2021. PMID: 33832350 No abstract available.
-
Response by Chan et al to Radico et al Regarding Article, "Effect of the 2017 European Guidelines on Reclassification of Severe Aortic Stenosis and Its Influence on Management Decisions for Initially Asymptomatic Aortic Stenosis".Circ Cardiovasc Imaging. 2021 Apr;14(4):e012487. doi: 10.1161/CIRCIMAGING.121.012487. Epub 2021 Apr 9. Circ Cardiovasc Imaging. 2021. PMID: 33877872 No abstract available.
Similar articles
-
Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.Circulation. 2025 Jun 3;151(22):1550-1564. doi: 10.1161/CIRCULATIONAHA.125.074425. Epub 2025 Mar 31. Circulation. 2025. PMID: 40163596 Free PMC article. Clinical Trial.
-
Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial.Circulation. 2022 Mar;145(9):648-658. doi: 10.1161/CIRCULATIONAHA.121.057639. Epub 2021 Nov 13. Circulation. 2022. PMID: 34779220 Clinical Trial.
-
Prognostic value of NT-proBNP and an adapted monin score in patients with asymptomatic aortic stenosis.Rev Esp Cardiol (Engl Ed). 2014 Jan;67(1):52-7. doi: 10.1016/j.rec.2013.06.020. Epub 2013 Oct 20. Rev Esp Cardiol (Engl Ed). 2014. PMID: 24774264
-
Watchful waiting care or early intervention in asymptomatic severe aortic stenosis: Where we are.Arch Cardiovasc Dis. 2021 Jan;114(1):59-72. doi: 10.1016/j.acvd.2020.07.002. Epub 2020 Nov 3. Arch Cardiovasc Dis. 2021. PMID: 33153947 Review.
-
Natriuretic peptides in the management of aortic stenosis.Curr Cardiol Rep. 2009 Mar;11(2):85-93. doi: 10.1007/s11886-009-0014-z. Curr Cardiol Rep. 2009. PMID: 19236823 Review.
Cited by
-
Moderate Aortic Stenosis: What is it and When Should We Intervene?Interv Cardiol. 2021 May 27;16:e09. doi: 10.15420/icr.2021.04. eCollection 2021 Apr. Interv Cardiol. 2021. PMID: 34188693 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials